HEMOGLOBIN

Scope & Guideline

Fostering collaboration in blood research and beyond.

Introduction

Explore the comprehensive scope of HEMOGLOBIN through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore HEMOGLOBIN in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0363-0269
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1976 to 2024
AbbreviationHEMOGLOBIN / Hemoglobin
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'HEMOGLOBIN' primarily focuses on research related to hemoglobinopathies and thalassemia, providing a platform for the latest findings in genetic mutations, clinical management strategies, and treatment advancements. Its core areas include genetic studies, clinical trials, and innovative therapeutic approaches.
  1. Genetic and Molecular Characterization of Hemoglobin Variants:
    The journal publishes studies that explore the genetic basis of various hemoglobinopathies, including sickle cell disease and thalassemia, focusing on novel mutations and their implications for disease phenotype.
  2. Clinical Management and Treatment Approaches:
    Research on clinical practices, treatment efficacy, and management strategies for patients with hemoglobin disorders is a key focus, including studies on iron chelation therapy, hydroxyurea, and stem cell transplantation.
  3. Public Health and Screening Initiatives:
    The journal emphasizes public health strategies for screening and managing hemoglobin disorders, particularly in high-prevalence regions, aiming to reduce the burden of these diseases through early detection.
  4. Innovative Therapeutic Strategies:
    It highlights advancements in gene therapy, targeted treatments, and novel drug development aimed at improving patient outcomes for those suffering from hemoglobinopathies.
  5. Epidemiological Studies and Risk Factors:
    The journal frequently publishes epidemiological research that assesses the prevalence, risk factors, and comorbidities associated with hemoglobin disorders across different populations.
Recent publications in 'HEMOGLOBIN' indicate a clear trend towards innovative research themes that are gaining traction. These themes reflect the evolving landscape of hemoglobinopathy research, particularly in genetics and personalized medicine.
  1. Gene Therapy and Precision Medicine:
    There is a notable increase in studies focusing on gene therapy as a treatment for hemoglobin disorders, highlighting its potential to address the underlying genetic causes of diseases like sickle cell anemia and thalassemia.
  2. Utilization of Next-Generation Sequencing:
    The application of next-generation sequencing techniques to identify novel mutations and understand the genetic basis of hemoglobinopathies is becoming increasingly prominent in recent studies.
  3. Impact of COVID-19 on Hemoglobin Disorders:
    Research exploring the effects of COVID-19 on patients with hemoglobin disorders, including changes in disease management and outcomes, is an emerging area of interest.
  4. Quality of Life and Psychosocial Factors:
    There is a growing emphasis on studies that assess the quality of life and psychosocial factors affecting patients with hemoglobinopathies, reflecting a broader understanding of patient care.
  5. Novel Therapeutic Agents and Combination Therapies:
    Research into new therapeutic agents and combination treatments, particularly focusing on improving outcomes for patients with severe forms of hemoglobin diseases, is gaining momentum.

Declining or Waning

While 'HEMOGLOBIN' maintains a robust focus on various aspects of hemoglobinopathies, certain themes appear to be declining in prominence based on recent publications. This may reflect shifts in research priorities or advancements in understanding that have made some topics less central.
  1. Historical Perspectives on Thalassemia:
    Research focusing on historical accounts or retrospective studies of thalassemia has seen a decline, possibly due to a shift towards more contemporary clinical trials and genetic studies.
  2. Basic Hematological Studies:
    Papers that primarily report basic hematological parameters without a direct link to clinical outcomes or genetic insights seem to be less frequent, as the field moves towards more applied research.
  3. Global Comparisons of Thalassemia Management:
    While still relevant, comparative studies between different countries regarding thalassemia management strategies have become less common, likely as institutions focus more on localized and personalized medicine approaches.
  4. Older Diagnostic Techniques:
    The use of older diagnostic methods, such as simple electrophoresis without advanced sequencing, appears to be waning as new technologies like next-generation sequencing gain prominence.
  5. General Reviews without Novel Insights:
    The publication of general reviews that do not provide novel insights or applications related to hemoglobinopathies is declining, as the journal favors studies that contribute new knowledge or advancements in treatment.

Similar Journals

Blood Science

Enhancing Patient Care Through Scholarly Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Thalassemia Reports

Innovating the future of hemoglobinopathy management.
Publisher: MDPIISSN: 2039-4357Frequency: 4 issues/year

Thalassemia Reports is a distinguished journal dedicated to the field of hematology, focusing on the implications, management, and advancements related to thalassemia and related disorders. Published by MDPI, a renowned open-access publisher, this journal has been committed to disseminating high-quality research since its inception in 2011. With an ISSN of 2039-4357 and an E-ISSN of 2039-4365, it serves as an invaluable resource for researchers, clinicians, and students alike who are engaged in the study of hemoglobinopathies. The journal fosters easy access to peer-reviewed articles that contribute to the understanding and management of thalassemia, thus promoting collaborative efforts within the academic and medical communities. The open-access model ensures that critical findings are widely available to the global audience, enhancing knowledge exchange and innovation in the field.

LEUKEMIA

Your Premier Source for Leukemia Research
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

CONGENITAL ANOMALIES

Connecting science and practice in congenital anomalies.
Publisher: WILEYISSN: 0914-3505Frequency: 4 issues/year

CONGENITAL ANOMALIES is a notable journal published by WILEY, dedicated to advancing the understanding of congenital disorders and anomalies through high-quality research and clinical insights. With an ISSN of 0914-3505 and an E-ISSN of 1741-4520, this journal has been a key resource for professionals in the fields of pediatrics, embryology, and developmental biology since its inception in 1973, although coverage discontinued in Scopus after 2019 due to evolving standards in publication. The journal is ranked in the 48th percentile in the domain of pediatrics, as well as in the 26th and 14th percentiles respectively for embryology and developmental biology, placing it among respected publications in its category. Although it does not currently offer open access options, its contributions remain vital for researchers, healthcare professionals, and students seeking up-to-date information on congenital anomalies, their origins, and potential interventions. With a commitment to fostering knowledge in this critical area of health science, CONGENITAL ANOMALIES continues to play an important role in the intersection of scientific research and clinical practice.

Hematology Transfusion and Cell Therapy

Advancing knowledge in hematology and cell therapy.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

PEDIATRIC NEPHROLOGY

Shaping the landscape of pediatric nephrology, one study at a time.
Publisher: SPRINGERISSN: 0931-041XFrequency: 12 issues/year

Pediatric Nephrology, published by Springer, is a leading international journal dedicated to advancing the field of pediatric nephrology and enhancing the health of children with renal disorders. With its ISSN 0931-041X and E-ISSN 1432-198X, this esteemed journal has been in circulation since 1987 and has established itself as a vital resource for researchers and clinicians alike. Featuring a robust impact factor and categorized in Q1 for Pediatrics, Perinatology and Child Health, and Q2 for Nephrology, Pediatric Nephrology stands at the forefront of medical literature, reflecting its commitment to disseminating high-quality research. The journal is particularly noted for its comprehensive scope, encompassing clinical studies, innovative treatments, and cutting-edge research findings that shape pediatric kidney care. Located in Germany and reaching a global audience, this journal not only supports the academic community but also plays a crucial role in improving health outcomes for children worldwide. Access to its valuable content is essential for any practitioner or researcher invested in the evolving landscape of pediatric medicine.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Advancing ocular health through innovative research.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Clinical Pediatric Endocrinology

Championing innovative research in the field of pediatric endocrinology.
Publisher: JAPANESE SOC PEDIATRIC ENDOCRINOLOGYISSN: 0918-5739Frequency: 4 issues/year

Clinical Pediatric Endocrinology is a prestigious journal dedicated to advancing the field of pediatric endocrinology, published by the Japanese Society of Pediatric Endocrinology. With a respectable ISSN 0918-5739 and E-ISSN 1347-7358, this journal serves as a critical platform for innovative research spanning various aspects of endocrine disorders in children, including diabetes and metabolic conditions. Although it does not currently offer open access, it remains highly relevant in its category, being ranked in Q4 and Q3 tiers across multiple specialties as of 2023. With a publication history that spans from 1992 to 2024, this journal has contributed significantly to the literature, as evidenced by its inclusion in prominent databases. It invites submissions from researchers and practitioners worldwide, aiming to facilitate knowledge sharing and improve clinical practices in pediatric endocrinology. For those dedicated to enhancing care outcomes in children with endocrine disorders, Clinical Pediatric Endocrinology provides essential insights and fosters a community of engaged professionals.

JOURNAL OF GENE MEDICINE

Elevating Standards in Gene Medicine Research
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Hormone Research in Paediatrics

Bridging research and practice for young patients.
Publisher: KARGERISSN: 1663-2818Frequency: 12 issues/year

Hormone Research in Paediatrics, published by KARGER, is a leading international journal dedicated to advancing the field of pediatric endocrinology. With its ISSN 1663-2818 and E-ISSN 1663-2826, it serves as a vital resource for researchers and professionals focused on the hormonal aspects affecting children's health. Housed in Switzerland, the journal benefits from a strong academic reputation and ranks in the prestigious Q1 category in Pediatrics, Perinatology, and Child Health, as well as maintaining Q2 status in Endocrinology, Diabetes, and Metabolism. Covering a time span from its inception in 1970 to the present day, Hormone Research in Paediatrics is committed to publishing high-quality original research, reviews, and clinical studies, making crucial contributions to our understanding of pediatric hormonal disorders and treatments. The journal incorporates open access options, fostering wider dissemination and accessibility of vital research findings, thus ensuring that significant advancements reach academics, professionals, and students globally.